CliffBio
biologic

Cutaquig

Immune Globulin Subcutaneous (Human)-hipp

Loss of exclusivityDecember 2030projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameCutaquig
Active ingredientImmune Globulin Subcutaneous (Human)-hipp
Strength2G/12ML
Dosage formSolution
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2018
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cutaquig patent cliff — loss of exclusivity December 2030 | CliffBio